优化转移性黑色素瘤的向治疗:使用恩科拉费尼布和特拉美提尼布组合,超出标准方案
François Pélouard1, Valérie Chedru-Legros2, Catherine Nganoa3
1Dermatology Department, Caen University Hospital. francoispelouard@gmail.com.
Dermatology reports
|April 16, 2025
概括
一种新的BRAF和MEK抑制剂组合,encorafenib-trametinib,在转移性黑色素瘤患者中表现出极好的耐受性和完全的瘤反应. 这种非标准的向治疗方法为那些经历了标准治疗的严重不良事件的患者提供了一个有希望的替代方案.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
背景情况:
- 转移性黑色素瘤的治疗通常涉及BRAF抑制剂 (BRAFi) 和MEK抑制剂 (MEKi) 的组合.
- 标准BRAFi/MEKi疗法可能会导致严重的不良事件 (AE),限制治疗持续时间或适用性.
- 现有有限的BRAFi/MEKi组合在市场上销售,需要探索替代治疗策略.
研究的目的:
- 报告一个转移性黑色素瘤病例,用非标准的BRAFi/MEKi组合治疗.
- 评估恩科拉费尼布-特拉美丁尼布在患有治疗限制性副作用的患者的疗效和耐受性.
- 探索BRAF突变黑色素瘤中替代向治疗组合的潜力.
主要方法:
- 一个45岁的男性患有第三期BRAFV600E突变黑色素瘤的病例报告.
- 连续使用标准的BRAFi/MEKi组合 (达布拉芬尼布-特拉美丁尼布,恩科拉芬尼布-比尼米丁尼布) 和免疫检查点抑制剂.
- 在治疗失败和AEs后,使用非标准的encorafenib-trametinib组合重新挑战.
- 基于证据的药理学分析,以了解治疗结果.
主要成果:
- 患者在标准BRAFi/MEKi组合下出现严重发烧和消化系统的副作用,导致治疗中止.
- 非标准的恩科拉费尼布-特拉美替尼布组合显示出显著的耐受性.
- 实现了完全的瘤反应,并维持了39个月.
- 这代表了这种特定组合的第一个报告的疗效案例.
结论:
- 非标准的BRAFi/MEKi组合,如恩科拉费尼布-特拉美丁尼布,可以在转移性黑色素瘤中有效且耐受良好.
- 这种方法为不能容忍标准向治疗的患者提供了可行的选择.
- 对替代BRAFi/MEKi组合进行进一步的研究是有必要的,以改善患者的治疗结果.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy
404
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
404
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K


